Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Germany's Pistorius: NATO protects Europe from Iranian missiles- Change Your Home into an Exercise center with These Famous Wellness Gadgets
- Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Illumina unveils dataset to speed up AI-powered drug discovery
- Pick Your Favored method of transportation
- Find Your Ideal Tea: Six Particular Assortments
- Whale stranded in the Baltic Sea swims free again. It still faces a tough task
- What to know about King Charles III's cancer treatment and his message to the public
